Volume 26, Issue 13 p. 2431-2434
Brief Report

Levetiracetam in primary orthostatic tremor: A double-blind placebo-controlled crossover study§

Helge Hellriegel MD

Helge Hellriegel MD

Department of Neurology, Christian-Albrechts-University, Kiel, Germany

Search for more papers by this author
Jan Raethjen MD, PhD

Corresponding Author

Jan Raethjen MD, PhD

Department of Neurology, Christian-Albrechts-University, Kiel, Germany

Department of Neurology, University Hospital Schleswig- Holstein, Campus Kiel, Haus 41, Arnold-Heller-Str. 3, 24105 Kiel, GermanySearch for more papers by this author
G. Deuschl MD, PhD

G. Deuschl MD, PhD

Department of Neurology, Christian-Albrechts-University, Kiel, Germany

Search for more papers by this author
Jens Volkmann MD, PhD

Jens Volkmann MD, PhD

Department of Neurology, Christian-Albrechts-University, Kiel, Germany

Search for more papers by this author
First published: 23 September 2011
Citations: 17

Funding agencies: This study was sponsored by UCB Pharma GmbH.

Relevant conflicts of interest/financial disclosures: Nothing to report.

§

Full financial disclosures and author roles may be found in the online version of this article.

Abstract

Background:

In a double-blind crossover study we evaluated the antitremor effect of a 4-week treatment with either escalating dosages of levetiracetam or placebo in orthostatic tremor.

Methods:

Twelve patients with orthostatic tremor participated in the study. Primary end point was improvement in stance duration. Secondary end points were total track length of the sway path and tremor total power. The patients' impression of impairment was assessed by a visual analog scale and quality of life by the SF-36.

Results:

We found no significant effect of dosage or treatment on stance duration (P = .175), total track length (P = .690), total power (P = .280), or visual analog scale (P =.735). Neither was SF-36 differentially changed by levetiracetam or placebo (SF-36, Physical Component Summary: P = .079; SF-36, Mental Component Summary: P = .073). Side effects like dizziness, fatigue, or nausea were only mild to moderate.

Conclusions:

Levetiracetam is ineffective in the treatment of orthostatic tremor. © 2011 Movement Disorder Society